LATITUDE, a phase 3 double-blind, randomized trial of androgen deprivation therapy (ADT) with abiraterone acetate (AA) plus prednisone (P) or placebos (PBOs) in patients (pts) with newly diagnosed high-risk metastatic hormone-naive prostate cancer (mHNPC)

Yazar
Fizazi, K.
Chi, K.
Feyerabend, S.
Matsubara, N.
Rodriguez Antolin, A.
Alekseev, B.
Ozguroglu, M.
Ye, D.
Protheroe, A.
De Porre, P.
Kheoh, T.
Park, Y. C.
Todd, M.
Tran, N.
Fein, L.
Üst veri
Tüm öğe kaydını göster
Bağlantı
http://hdl.handle.net/20.500.12627/145899
Koleksiyonlar